China Shineway Pharmaceutical Group Reports 16.3% Drop in Nine-Month Turnover
Reuters
Nov 07
<a href="https://laohu8.com/S/CSWYY">China Shineway</a> Pharmaceutical Group Reports 16.3% Drop in Nine-Month Turnover
China Shineway Pharmaceutical Group Limited announced that its turnover for the nine months ended 30 September 2025 was RMB 2,415 million, representing a decrease of 16.3% compared to the same period in 2024. Turnover of injection products declined by 23.6% to RMB 786 million, soft capsule products decreased by 13.7% to RMB 337 million, granule products fell by 14.5% to RMB 391 million, TCM formula granule products dropped by 11.8% to RMB 726 million, and products in other forms decreased by 6.1% to RMB 175 million. Injection products, soft capsule products, granule products, and TCM formula granule products accounted for approximately 32.5%, 14.0%, 16.2%, and 30.1% of total turnover, respectively, during the period. The results are based on management accounts that have not been reviewed by auditors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Shineway Pharmaceutical Group Ltd. published the original content used to generate this news brief on November 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.